Recommendation for use of icosapent ethyl in final guidance by NICE
The National Institute for Health and Care Excellence (NICE) in the UK has issued a final guidance recommending icosapent ethyl for reimbursement and use across the National Health Service (NHS) in England and Wales. Use of icosapent ethyl helps to reduce risk of major CV events in patients with high CV risk who already take statins, and have elevated triglycerides (≥150 mg/dL [≥1.7 mmol/L]), controlled LDL-c between 1.04 mmol/L-2.60 mmol/L and established CVD.
This final guidance follows the previous draft guidance.
Source: press release Amarin, July 13 2022 Find here the NICE guidance on icosapent ethyl
Share this page with your colleagues and friends: